FOUND: Alloheme - What They Never Told You

CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans

CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion. Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas

MarketBeat · Jun 9

CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv

MarketBeat · Jun 7